Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

@inproceedings{Berman2011LongtermSA,
  title={Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder},
  author={Robert M. Berman and Michael E. Thase and Madhukar H. Trivedi and James A Hazel and Sabrina Vogel Marler and Robert D. McQuade and William H. Carson and Ross A. Baker and Ronald N. Marcus},
  booktitle={Neuropsychiatric disease and treatment},
  year={2011}
}
BACKGROUND Effective management of major depressive disorder often includes the long-term use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole has not been evaluated in a controlled setting. PATIENTS AND METHODS Patients (n = 706) completing one of two 14-week double-blind studies of aripiprazole augmentation, as well as de novo patients (n = 296) nonresponsive to current antidepressant therapy, were enrolled in this open-label study. Patients… CONTINUE READING
11 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Similar Papers

Loading similar papers…